- Home
- AGL vs PRTA Comparison
AGL vs PRTA Comparison
Compare AGL & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGL | PRTA |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.9M | 482.3M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AGL | PRTA |
|---|---|---|
| Price | $0.44 | $9.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 9 |
| Target Price | $2.77 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 8.7M | 363.4K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,060,530,000.00 | $814,000.00 |
| Revenue This Year | N/A | $1,395.77 |
| Revenue Next Year | $2.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.41 | N/A |
| 52 Week Low | $0.34 | $4.32 |
| 52 Week High | $6.08 | $16.16 |
Technical Indicators
Market Signals| Indicator | AGL | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 27.98 | 37.97 |
| Support Level | $0.36 | $8.80 |
| Resistance Level | $0.41 | $9.23 |
| Average True Range (ATR) | 0.07 | 0.51 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 10.12 | 13.24 |
Price Performance
Historical ComparisonAbout AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.